Spravato® (esketamine) is an FDA-approved medication specifically designed to treat depression for people who have not responded to other treatments. Approved by the U.S. Food and Drug Administration (FDA) in 2019 as a nasal spray for treatment-resistant depression, Spravato® offers a new option for patients who have not found relief with other treatments.
Spravato® works by acting on a pathway in the brain that affects glutamate, the most abundant neurotransmitter in the brain, helping to regulate mood and emotions. It is administered as a nasal spray and is typically used in combination with an oral antidepressant under the supervision of a healthcare professional at our Gilbert, Arizona location. Patients are closely monitored for at least two hours after administration.
While Spravato® has shown effectiveness in clinical trials for treating depression, it is important to note that it may have potential side effects, including dizziness, dissociation, and sedation. Additionally, it carries a risk of abuse and dependence, which requires patients to be enrolled in a Risk Evaluation and Mitigation Strategy (REMS) program to ensure safe use.
At Lighthouse Psychiatry, we offer both Spravato® and Ketamine infusion as treatment options for patients with treatment-resistant depression. If you or a loved one are struggling with depression, our team is dedicated to helping you determine the best approach to improve your mood and overall brain health.
Contact us today for assistance.
